These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 25296072)

  • 1. [Nodular lymphocyte-predominant Hodgkin lymphoma in children: clinical course, biology, and management].
    Gorde-Grosjean S; Guimard G; Lambilliotte A; Coulomb-Lhermine A; Montravers F; Landman-Parker J
    Bull Cancer; 2014 Sep; 101(9):881-90. PubMed ID: 25296072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-predominant Hodgkin lymphoma: what is the optimal treatment?
    Fanale M
    Hematology Am Soc Hematol Educ Program; 2013; 2013():406-13. PubMed ID: 24319212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modern management of lymphocyte-predominant Hodgkin lymphoma.
    Xing KH; Savage KJ
    Br J Haematol; 2013 May; 161(3):316-29. PubMed ID: 23398605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular lymphocyte predominant hodgkin lymphoma: biology, diagnosis and treatment.
    Goel A; Fan W; Patel AA; Devabhaktuni M; Grossbard ML
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):261-70. PubMed ID: 24650975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
    Hawkes EA; Wotherspoon A; Cunningham D
    Leuk Lymphoma; 2012 Mar; 53(3):354-61. PubMed ID: 21812538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management.
    Eichenauer DA; Engert A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):324-328. PubMed ID: 29222274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma.
    Maeda LS; Advani RH
    Curr Opin Oncol; 2009 Sep; 21(5):397-400. PubMed ID: 19606035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with CD30-positive lymphocyte-predominant (LP) cells.
    Seliem RM; Ferry JA; Hasserjian RP; Harris NL; Zukerberg LR
    J Hematop; 2011 Sep; 4(3):175. PubMed ID: 32288859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents--a comprehensive review of biology, clinical course and treatment options.
    Shankar A; Daw S
    Br J Haematol; 2012 Nov; 159(3):288-98. PubMed ID: 22994199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocyte-Rich Classical Hodgkin Lymphoma. A Case with Difficulty in Distinguishing from Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
    Sakai J; Tanae K; Takahashi N; Nagata K; Yoshino T; Tamaru J; Niitsu N
    J Clin Exp Hematop; 2015; 55(1):23-8. PubMed ID: 26106003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Li L; Luo XL
    Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):594-8. PubMed ID: 17243292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Savage KJ; Mottok A; Fanale M
    Semin Hematol; 2016 Jul; 53(3):190-202. PubMed ID: 27496311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center.
    Menke JR; Spinner MA; Natkunam Y; Warnke RA; Advani RH; Gratzinger DA
    Arch Pathol Lab Med; 2021 Jun; 145(6):753-758. PubMed ID: 32991677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year follow-up in the West of Scotland Cancer Network.
    Farrell K; McKay P; Leach M
    Leuk Lymphoma; 2011 Oct; 52(10):1920-8. PubMed ID: 21663507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.